Pulmonary Hypertension in Portugal: First Data from a Nationwide Registry

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2013 Nov 15

PMID 24228252

Citations 21

Authors

Rui Baptista

Jose Meireles

Ana Agapito

Graca Castro

Antonio Marinho Da Silva

Teresa Shiang

Fabienne Goncalves

Susana Robalo-Martins

Antonio Nunes-Diogo

Abilio Reis

Affiliations

Soon will be listed here.

Abstract

Introduction: Pulmonary arterial hypertension (PAH) is a rare disease that must be managed in specialized centers; therefore, the availability of epidemiological national data is critical.

Methods: We conducted a prospective, observational, and multicenter registry with a joint collaboration from five centers from Portugal and included adult incident patients with PAH or chronic thromboembolic pulmonary hypertension (CTEPH).

Results: Of the 79 patients enrolled in this study, 46 (58.2%) were classified as PAH and 33 patients (41.8%) as CTEPH. PAH patients had a mean age of 43.4 ± 16.4 years. Idiopathic PAH was the most common etiology (37%). At presentation, PAH patients had elevated right atrial pressure (RAP) (7.7 ± 5.9 mmHg) and mean pulmonary vascular resistance (11.4 ± 6.5 Wood units), with a low cardiac index (2.7 ± 1.1 L·min(-1)·m(-2)); no patient was under selective pulmonary vasodilators; however, at follow-up, most patients were on single (50%), double (28%), or triple (9%) combination vasodilator therapy. One-year survival was 93.5%, similar to CTEPH patients (93.9%), that were older (60.0 ± 12.5 years) and had higher RAP (11.0 ± 5.2 mmHg, P = 0.015).

Conclusions: We describe for the first time nationwide data on the diagnosis, management, and prognosis of PAH and CTEPH patients in Portugal. Clinical presentation and outcomes are comparable with those reported on other national registries.

Citing Articles

Survival, morbidity, and quality of life in pulmonary arterial hypertension patients: a systematic review of outcomes reported by population-based observational studies.

Reinders S, Didden E, Ong R Respir Res. 2024; 25(1):373.

PMID: 39415261 PMC: 11481430. DOI: 10.1186/s12931-024-02994-w.

Selexipag in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH-CTD): Real-world experience from EXPOSURE.

Gaine S, Escribano-Subias P, Muller A, Fernandes C, Fontana M, Remenova T Pulm Circ. 2024; 14(3):e12403.

PMID: 39076250 PMC: 11284239. DOI: 10.1002/pul2.12403.

Real-world evidence to advance knowledge in pulmonary hypertension: Status, challenges, and opportunities. A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative's Real-world Evidence Working....

Morland K, Gerges C, Elwing J, Visovatti S, Weatherald J, Gillmeyer K Pulm Circ. 2023; 13(4):e12317.

PMID: 38144948 PMC: 10739115. DOI: 10.1002/pul2.12317.

Incidence and outcomes of pulmonary hypertension in the Ireland.

Cullivan S, Lennon D, Meghani S, Minnock C, McCullagh B, Gaine S BMJ Open Respir Res. 2022; 9(1).

PMID: 35768152 PMC: 9244715. DOI: 10.1136/bmjresp-2022-001272.

Prevalence, incidence, and survival of pulmonary arterial hypertension: A systematic review for the global burden of disease 2020 study.

Emmons-Bell S, Johnson C, Boon-Dooley A, Corris P, Leary P, Rich S Pulm Circ. 2022; 12(1):e12020.

PMID: 35506069 PMC: 9052982. DOI: 10.1002/pul2.12020.

References

Hachulla E, Gressin V, Guillevin L, Carpentier P, Diot E, Sibilia J . Early detection of pulmonary arterial hypertension in systemic sclerosis: a French nationwide prospective multicenter study. Arthritis Rheum. 2005; 52(12):3792-800. DOI: 10.1002/art.21433. View

Thenappan T, Shah S, Rich S, Gomberg-Maitland M . A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J. 2007; 30(6):1103-10. DOI: 10.1183/09031936.00042107. View

Ghofrani H, Distler O, Gerhardt F, Gorenflo M, Grunig E, Haefeli W . Treatment of pulmonary arterial hypertension (PAH): updated Recommendations of the Cologne Consensus Conference 2011. Int J Cardiol. 2012; 154 Suppl 1:S20-33. DOI: 10.1016/S0167-5273(11)70490-9. View

McLaughlin V . Looking to the future: a new decade of pulmonary arterial hypertension therapy. Eur Respir Rev. 2011; 20(122):262-9. PMC: 9487745. DOI: 10.1183/09059180.00006411. View

Humbert M, Sitbon O, Simonneau G . Treatment of pulmonary arterial hypertension. N Engl J Med. 2004; 351(14):1425-36. DOI: 10.1056/NEJMra040291. View

Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V . Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med. 2006; 173(9):1023-30. DOI: 10.1164/rccm.200510-1668OC. View

DAlonzo G, Barst R, Ayres S, Bergofsky E, Brundage B, Detre K . Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med. 1991; 115(5):343-9. DOI: 10.7326/0003-4819-115-5-343. View

HOPKINS W, Ochoa L, Richardson G, Trulock E . Comparison of the hemodynamics and survival of adults with severe primary pulmonary hypertension or Eisenmenger syndrome. J Heart Lung Transplant. 1996; 15(1 Pt 1):100-5. View

Appelbaum L, Yigla M, Bendayan D, Reichart N, Fink G, Priel I . Primary pulmonary hypertension in Israel: a national survey. Chest. 2001; 119(6):1801-6. DOI: 10.1378/chest.119.6.1801. View

10.

Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V . Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010; 122(2):156-63. DOI: 10.1161/CIRCULATIONAHA.109.911818. View

11.

Pengo V, Lensing A, Prins M, Marchiori A, Davidson B, Tiozzo F . Incidence of chronic thromboembolic pulmonary hypertension after pulmonary embolism. N Engl J Med. 2004; 350(22):2257-64. DOI: 10.1056/NEJMoa032274. View

12.

Jais X, DArmini A, Jansa P, Torbicki A, Delcroix M, Ghofrani H . Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic pulmonary hypertension), a randomized, placebo-controlled trial. J Am Coll Cardiol. 2008; 52(25):2127-34. DOI: 10.1016/j.jacc.2008.08.059. View

13.

Peacock A, Murphy N, McMurray J, Caballero L, Stewart S . An epidemiological study of pulmonary arterial hypertension. Eur Respir J. 2007; 30(1):104-9. DOI: 10.1183/09031936.00092306. View

14.

Fischler M, Speich R, Dorschner L, Nicod L, Domenighetti G, Tamm M . Pulmonary hypertension in Switzerland: treatment and clinical course. Swiss Med Wkly. 2008; 138(25-26):371-8. DOI: 10.4414/smw.2008.11914. View

15.

Jing Z, Xu X, Han Z, Wu Y, Deng K, Wang H . Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest. 2007; 132(2):373-9. DOI: 10.1378/chest.06-2913. View

16.

Galie N, Rubin L, Hoeper M, Jansa P, Al-Hiti H, Meyer G . Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet. 2008; 371(9630):2093-100. DOI: 10.1016/S0140-6736(08)60919-8. View

17.

Tueller C, Stricker H, Soccal P, Tamm M, Aubert J, Maggiorini M . Epidemiology of pulmonary hypertension: new data from the Swiss registry. Swiss Med Wkly. 2008; 138(25-26):379-84. DOI: 10.4414/smw.2008.11915. View

18.

Galie N, Hoeper M, Humbert M, Torbicki A, Vachiery J, Barbera J . Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the.... Eur Heart J. 2009; 30(20):2493-537. DOI: 10.1093/eurheartj/ehp297. View

19.

Hughes R, Jais X, Bonderman D, Suntharalingam J, Humbert M, Lang I . The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study. Eur Respir J. 2006; 28(1):138-43. DOI: 10.1183/09031936.06.00135905. View

20.

Simonneau G, Robbins I, Beghetti M, Channick R, Delcroix M, Denton C . Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol. 2009; 54(1 Suppl):S43-S54. DOI: 10.1016/j.jacc.2009.04.012. View